IMR Press / EJGO / Volume 28 / Issue 5 / pii/2007192

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Original Research

Use of lysophosphatidic acid in the management of benign and malignant ovarian tumors

Show Less
1 Department of Obstetrics and Gynecology, University Medical Centre, Ljubljana, Slovenia
2 Krka d.d. Novo Mesta, Research and Development, Novo Mesta, Slovenia
3 Institute of Clinical Chemistry and Biochemistry, University Medical Centre, Ljubljana, Slovenia
4 Faculty of Chemistry and Chemical Technology at University of Ljubljana, Slovenia
Eur. J. Gynaecol. Oncol. 2007, 28(5), 394–399;
Published: 10 October 2007

Objective: To establish whether LPA determination improves the differentiation of benign from malignant ovarian tumors Methods: Total LPA and LPA species in the serum were determined using a novel method in 142 patients with ultrasound (US) suspecious ovarian tumors and in 78 healthy women. All women underwent determination of CAl25 in the serum, a vaginal US examination and morphology scoring of the tumor. Results: The levels of total LPA and its species in women with ovarian tumors were significantly higher from those in healthy women (p < 0.001). No significant difference was found in the levels of total LPA or any of its species between the women with benign and those with malignant ovarian tumors. Conclusions: Determination of serum LPA would be an appropriate test for ovarian tumor presence, especially in women of reproductive age. The method however does not differentiate benign from malignant ovarian tumors.

Lysophosphatidic acid
Benign and malignant ovarian tumors
Predictive value
Back to top